Patient characteristics
Patient . | UPN 1574 . | UPN 4103 . | UPN 7826 . |
|---|---|---|---|
| Age, y | 43 | 39 | 31 |
| Diagnosis at transplantation | CML, 2nd CP/AP | CML, AP | CML, CP |
| Donor type | MMRD | MRD | MUD |
| Conditioning | Cy/TBI (1st transplantation); Bu/Cy (2nd transplantation) | Cy/TBI | Cy/TBI |
| GVHD prophylaxis | CSP/prednisone | CSP/MTX | CSP/MTX/anti—T-cell mAb |
| Acute GVHD | None (1st transplantation); grade 3 (2nd transplantation) | None | None |
| Chronic GVHD | Extensive | Limited | Limited |
| Months to relapse after last transplantation | 69 | 59 | 9 |
| Months from relapse to HyTK-positive DLI | 10 | 84 | 62 |
| Disease status at time of HyTK-positive DLI | CML, AP | Cytogenetic relapse | CML, AP |
| % donor cells pre DLI: BM/PB | 95/90 | 30/99 | 25/75 |
| HyTK-positive DLI dose, CD3+ per kg | |||
| First infusion | 0.1 × 108/kg | 0.5 × 108/kg | 0.1 × 108/kg |
| Second infusion | 0.5 × 108/kg | None | None |
Patient . | UPN 1574 . | UPN 4103 . | UPN 7826 . |
|---|---|---|---|
| Age, y | 43 | 39 | 31 |
| Diagnosis at transplantation | CML, 2nd CP/AP | CML, AP | CML, CP |
| Donor type | MMRD | MRD | MUD |
| Conditioning | Cy/TBI (1st transplantation); Bu/Cy (2nd transplantation) | Cy/TBI | Cy/TBI |
| GVHD prophylaxis | CSP/prednisone | CSP/MTX | CSP/MTX/anti—T-cell mAb |
| Acute GVHD | None (1st transplantation); grade 3 (2nd transplantation) | None | None |
| Chronic GVHD | Extensive | Limited | Limited |
| Months to relapse after last transplantation | 69 | 59 | 9 |
| Months from relapse to HyTK-positive DLI | 10 | 84 | 62 |
| Disease status at time of HyTK-positive DLI | CML, AP | Cytogenetic relapse | CML, AP |
| % donor cells pre DLI: BM/PB | 95/90 | 30/99 | 25/75 |
| HyTK-positive DLI dose, CD3+ per kg | |||
| First infusion | 0.1 × 108/kg | 0.5 × 108/kg | 0.1 × 108/kg |
| Second infusion | 0.5 × 108/kg | None | None |
BM indicates bone marrow; PB, peripheral blood; MMRD, mismatched related donor; MRD, matched related donor; MUD, matched unrelated donor; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; CSP, cyclosporine A; MTX, methotrexate.